| Mr Matthugh Bennett, CRNA | |
|
1 Cooper Plz, Camden, NJ 08103 | |
| (856) 342-2425 | |
| Not Available |
| Full Name | Mr Matthugh Bennett |
|---|---|
| Gender | Male |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 10 Years |
| Location | 1 Cooper Plz, Camden, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073911772 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | R212706 (Maryland) | Secondary |
| 367500000X | Nurse Anesthetist, Certified Registered | 26NJ00824500 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Christiana Hospital | Newark, DE | Hospital |
| Jfk Medical Center | Edison, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| New Jersey Healthcare Specialists Pc | 2668385253 | 554 |
| Anesthesia Services Pa | 9537064498 | 188 |
News Archive
Symbollon Pharmaceuticals, Inc. has announced today that the retail launch of IoGen™, its dietary supplement for women's breast health, will commence in February. IoGen™ is the first dietary supplement formulated to promote breast health for women. Initially, the Company plans to market IoGen™ through its own retail web site, which is currently being developed by Atech Solutions.
Researchers at the University of Southampton have identified how new checkpoint inhibitor treatments for cancer can activate tuberculosis in some patients.
Researchers from Chronix Biomedical and The University of Texas MD Anderson Cancer Center today announced that results from a pilot study demonstrating the utility of cell-free DNA (cfDNA) blood tests as a companion diagnostic for breast cancer patients are to be reported in a poster presentation titled "Modulation of breast cancer cell-free DNA with surgical resection" (Abstract #11060) at the American Society of Clinical Oncology Annual Meeting (ASCO 2013) being held from May 31 through June 4, 2013 in Chicago. The blood test detects cfDNA that is released into the blood stream by damaged and dying cancer cells.
Echo Therapeutics, Inc., a company developing its needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude(TM) SkinPrep System for transdermal drug delivery, announced today that it has entered into definitive agreements with accredited and institutional investors to raise approximately $3 million through the sale of approximately 2.37 million shares of common stock at $1.25 per share through a private placement transaction.
New research from independent research organization MindMetre has revealed that many NHS Trusts are not complying with ‘safer sharps' rules, putting NHS employees at unnecessary risk of ‘needlestick' injuries and possible blood-borne infections such as hepatitis and HIV.
› Verified 9 days ago
| Entity Name | New Jersey Healthcare Specialists Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174585780 PECOS PAC ID: 2668385253 Enrollment ID: O20031110000555 |
News Archive
Symbollon Pharmaceuticals, Inc. has announced today that the retail launch of IoGen™, its dietary supplement for women's breast health, will commence in February. IoGen™ is the first dietary supplement formulated to promote breast health for women. Initially, the Company plans to market IoGen™ through its own retail web site, which is currently being developed by Atech Solutions.
Researchers at the University of Southampton have identified how new checkpoint inhibitor treatments for cancer can activate tuberculosis in some patients.
Researchers from Chronix Biomedical and The University of Texas MD Anderson Cancer Center today announced that results from a pilot study demonstrating the utility of cell-free DNA (cfDNA) blood tests as a companion diagnostic for breast cancer patients are to be reported in a poster presentation titled "Modulation of breast cancer cell-free DNA with surgical resection" (Abstract #11060) at the American Society of Clinical Oncology Annual Meeting (ASCO 2013) being held from May 31 through June 4, 2013 in Chicago. The blood test detects cfDNA that is released into the blood stream by damaged and dying cancer cells.
Echo Therapeutics, Inc., a company developing its needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude(TM) SkinPrep System for transdermal drug delivery, announced today that it has entered into definitive agreements with accredited and institutional investors to raise approximately $3 million through the sale of approximately 2.37 million shares of common stock at $1.25 per share through a private placement transaction.
New research from independent research organization MindMetre has revealed that many NHS Trusts are not complying with ‘safer sharps' rules, putting NHS employees at unnecessary risk of ‘needlestick' injuries and possible blood-borne infections such as hepatitis and HIV.
› Verified 9 days ago
| Entity Name | Cooper Anesthesia Associates Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447207147 PECOS PAC ID: 1254236672 Enrollment ID: O20031126000651 |
News Archive
Symbollon Pharmaceuticals, Inc. has announced today that the retail launch of IoGen™, its dietary supplement for women's breast health, will commence in February. IoGen™ is the first dietary supplement formulated to promote breast health for women. Initially, the Company plans to market IoGen™ through its own retail web site, which is currently being developed by Atech Solutions.
Researchers at the University of Southampton have identified how new checkpoint inhibitor treatments for cancer can activate tuberculosis in some patients.
Researchers from Chronix Biomedical and The University of Texas MD Anderson Cancer Center today announced that results from a pilot study demonstrating the utility of cell-free DNA (cfDNA) blood tests as a companion diagnostic for breast cancer patients are to be reported in a poster presentation titled "Modulation of breast cancer cell-free DNA with surgical resection" (Abstract #11060) at the American Society of Clinical Oncology Annual Meeting (ASCO 2013) being held from May 31 through June 4, 2013 in Chicago. The blood test detects cfDNA that is released into the blood stream by damaged and dying cancer cells.
Echo Therapeutics, Inc., a company developing its needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude(TM) SkinPrep System for transdermal drug delivery, announced today that it has entered into definitive agreements with accredited and institutional investors to raise approximately $3 million through the sale of approximately 2.37 million shares of common stock at $1.25 per share through a private placement transaction.
New research from independent research organization MindMetre has revealed that many NHS Trusts are not complying with ‘safer sharps' rules, putting NHS employees at unnecessary risk of ‘needlestick' injuries and possible blood-borne infections such as hepatitis and HIV.
› Verified 9 days ago
| Entity Name | Chc Pain Management Center, Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538109913 PECOS PAC ID: 0648265777 Enrollment ID: O20040419000397 |
News Archive
Symbollon Pharmaceuticals, Inc. has announced today that the retail launch of IoGen™, its dietary supplement for women's breast health, will commence in February. IoGen™ is the first dietary supplement formulated to promote breast health for women. Initially, the Company plans to market IoGen™ through its own retail web site, which is currently being developed by Atech Solutions.
Researchers at the University of Southampton have identified how new checkpoint inhibitor treatments for cancer can activate tuberculosis in some patients.
Researchers from Chronix Biomedical and The University of Texas MD Anderson Cancer Center today announced that results from a pilot study demonstrating the utility of cell-free DNA (cfDNA) blood tests as a companion diagnostic for breast cancer patients are to be reported in a poster presentation titled "Modulation of breast cancer cell-free DNA with surgical resection" (Abstract #11060) at the American Society of Clinical Oncology Annual Meeting (ASCO 2013) being held from May 31 through June 4, 2013 in Chicago. The blood test detects cfDNA that is released into the blood stream by damaged and dying cancer cells.
Echo Therapeutics, Inc., a company developing its needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude(TM) SkinPrep System for transdermal drug delivery, announced today that it has entered into definitive agreements with accredited and institutional investors to raise approximately $3 million through the sale of approximately 2.37 million shares of common stock at $1.25 per share through a private placement transaction.
New research from independent research organization MindMetre has revealed that many NHS Trusts are not complying with ‘safer sharps' rules, putting NHS employees at unnecessary risk of ‘needlestick' injuries and possible blood-borne infections such as hepatitis and HIV.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Matthugh Bennett, CRNA 1 Federal St Ste Sw200, Camden, NJ 08103-1155 Ph: (856) 356-4924 | Mr Matthugh Bennett, CRNA 1 Cooper Plz, Camden, NJ 08103 Ph: (856) 342-2425 |
News Archive
Symbollon Pharmaceuticals, Inc. has announced today that the retail launch of IoGen™, its dietary supplement for women's breast health, will commence in February. IoGen™ is the first dietary supplement formulated to promote breast health for women. Initially, the Company plans to market IoGen™ through its own retail web site, which is currently being developed by Atech Solutions.
Researchers at the University of Southampton have identified how new checkpoint inhibitor treatments for cancer can activate tuberculosis in some patients.
Researchers from Chronix Biomedical and The University of Texas MD Anderson Cancer Center today announced that results from a pilot study demonstrating the utility of cell-free DNA (cfDNA) blood tests as a companion diagnostic for breast cancer patients are to be reported in a poster presentation titled "Modulation of breast cancer cell-free DNA with surgical resection" (Abstract #11060) at the American Society of Clinical Oncology Annual Meeting (ASCO 2013) being held from May 31 through June 4, 2013 in Chicago. The blood test detects cfDNA that is released into the blood stream by damaged and dying cancer cells.
Echo Therapeutics, Inc., a company developing its needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude(TM) SkinPrep System for transdermal drug delivery, announced today that it has entered into definitive agreements with accredited and institutional investors to raise approximately $3 million through the sale of approximately 2.37 million shares of common stock at $1.25 per share through a private placement transaction.
New research from independent research organization MindMetre has revealed that many NHS Trusts are not complying with ‘safer sharps' rules, putting NHS employees at unnecessary risk of ‘needlestick' injuries and possible blood-borne infections such as hepatitis and HIV.
› Verified 9 days ago
Winter E. Skelly, CRNA, APN Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1 Cooper Plz Dept Of, Camden, NJ 08103 Phone: 856-342-2425 | |
Balaishe Boakai Ballo, Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 1600 Haddon Ave, Camden, NJ 08103 Phone: 856-757-3500 | |
Michael Phillip Hoess, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1 Cooper Plz, Camden, NJ 08103 Phone: 856-342-2425 | |
Amy Tsao, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 1 Cooper Plz Dept Of, Camden, NJ 08103 Phone: 856-382-6500 | |
Maria Dinnah Eclavia-dy, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1 Cooper Plz, Cooper Anesthesia Associates, Camden, NJ 08103 Phone: 856-342-2425 | |
Meredith Christina Defusco, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1 Cooper Plz, Camden, NJ 08103 Phone: 856-342-2425 | |
Amber Klein, APN-A CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1600 Haddon Ave, Camden, NJ 08103 Phone: 856-757-3500 |